OPKO Health (NASDAQ:OPK) Announces Earnings Results

OPKO Health (NASDAQ:OPK) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03, Zacks reports. The firm had revenue of $148.50 million for the quarter, compared to analysts’ expectations of $139.76 million. OPKO Health had a negative return on equity of 13.67% and a negative net margin of 28.10%.The business’s revenue for the quarter was down 19.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.01 EPS.

Here are the key takeaways from OPKO Health’s conference call:

• OPKO completed a second major asset sale of BioReference’s oncology assets and repositioned BioReference as a streamlined, regionally focused clinical lab with a national 4Kscore franchise, which management says positions the diagnostics business for sustained profitable growth in 2026.
• The company struck a collaboration with Regeneron (potentially >$1 billion in milestones plus royalties) and has an EBV vaccine partnership with Merck, providing non-dilutive funding and external development/commercial support for ModeX programs.
• ModeX clinical progress: MDX-2001 has dosed >25 patients with dose escalation showing tolerability and early efficacy signals, MDX-2004 (immune rejuvenator) and MDX-2003 (CD19/CD20 tetraspecific) are in/entering Phase 1, and multiple readouts/phase advances are expected through 2026.
• OPKO entered 2026 with a strong liquidity position (reported $369 million in cash/restricted cash) and an active buyback program (34.6M shares repurchased in 2025; ~$113M remaining authorization), which management is using alongside R&D investments.
• Financial headwinds remain as Q4 revenue declined to $148.5M (from $183.6M) after the divestiture, Q4 net loss was $31.3M, and full-year 2026 guidance implies heavy spending with total costs of $725M–$750M driven by increased R&D investment.

OPKO Health Trading Up 2.1%

NASDAQ:OPK traded up $0.03 during trading hours on Friday, hitting $1.23. The company had a trading volume of 1,882,796 shares, compared to its average volume of 2,912,857. The company has a 50-day moving average of $1.27 and a 200 day moving average of $1.36. The company has a current ratio of 3.70, a quick ratio of 3.32 and a debt-to-equity ratio of 0.25. The company has a market cap of $940.43 million, a P/E ratio of -4.90 and a beta of 1.47. OPKO Health has a 1 year low of $1.11 and a 1 year high of $2.04.

Key OPKO Health News

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: Q4 results beat consensus: OPKO reported a loss of $0.04/share vs. a consensus loss of $0.07 and revenue of $148.5M that topped Street estimates, signaling better-than-expected near-term performance. Read More.
• Positive Sentiment: High‑value Regeneron collaboration: OPKO (ModeX) entered a research deal with Regeneron to develop multispecific antibodies with upfront and program-level milestones; company says the collaboration could exceed $1B if multiple products succeed — a material long‑term commercial opportunity. Read More.
• Positive Sentiment: Pipeline progress and strategic wins: multiple programs advanced — MDX2003 cleared for Phase 1 (Australia), MDX2004/MDX2001 data presented at major meetings, Merck completed a Phase 1 EBV vaccine trial, and BARDA‑supported MDX2301 is slated for trials — these reduce binary risk on key assets. Read More.
• Positive Sentiment: Healthy liquidity and buyback capacity: cash and equivalents were $369.1M at year‑end and ~$112.7M of the repurchase authorization remains, giving management optionality to support the share price or fund development. Read More.
• Neutral Sentiment: Investor outreach: management will hold one‑on‑one meetings at the Jefferies Biotech on the Beach summit (March 10–11), offering additional transparency for investors but no immediate financial impact. Read More.
• Negative Sentiment: Revenue contraction and margin pressure: consolidated Q4 revenue fell to $148.5M from $183.6M a year earlier (largely due to asset sales) and Zacks flagged contracting gross margin — a reminder underlying top‑line growth remains uneven. Read More.
• Negative Sentiment: Wider operating losses & lower-than‑Street revenue guide: OPKO reported a Q4 net loss (~$31.3M) and issued 2026 revenue guidance of $530–560M, below some consensus figures — guidance that could keep near‑term sentiment pressured until growth visibility improves. Read More.

Institutional Trading of OPKO Health

Several institutional investors and hedge funds have recently bought and sold shares of the business. StoneX Group Inc. purchased a new position in OPKO Health during the 4th quarter worth $27,000. Zacks Investment Management purchased a new position in shares of OPKO Health in the fourth quarter valued at $27,000. Cibc World Markets Corp purchased a new stake in shares of OPKO Health in the 4th quarter worth about $34,000. EP Wealth Advisors LLC acquired a new stake in OPKO Health in the 4th quarter valued at about $37,000. Finally, Norges Bank acquired a new position in OPKO Health during the second quarter worth about $52,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Analyst Ratings Changes

OPK has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. Jefferies Financial Group restated a “hold” rating and issued a $1.60 price target (down from $2.00) on shares of OPKO Health in a research note on Thursday, October 30th. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research report on Thursday, October 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. assumed coverage on shares of OPKO Health in a report on Thursday, November 20th. They set a “neutral” rating on the stock. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, OPKO Health has an average rating of “Hold” and an average target price of $2.28.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.